|
Consolidated Statements of Operations (USD $)
In Thousands, except Share data, unless otherwise specified
|
12 Months Ended |
|
Dec. 31, 2013
|
Dec. 31, 2012
|
Dec. 31, 2011
|
| Revenues: |
|
|
|
| Product sales |
$ 257,922 |
$ 215,879 |
$ 202,409 |
| Contracts and grants |
54,823 |
66,009 |
70,975 |
| Total revenues |
312,745 |
281,888 |
273,384 |
| Operating expenses: |
|
|
|
| Cost of product sales |
62,127 |
46,077 |
42,171 |
| Research and development |
119,933 |
120,226 |
124,832 |
| Selling, general and administrative |
87,883 |
76,018 |
74,282 |
| Impairment of in-process research and development |
0 |
9,600 |
0 |
| Income from operations |
42,802 |
29,967 |
32,099 |
| Other income (expense): |
|
|
|
| Interest income |
139 |
134 |
105 |
| Interest expense |
0 |
(6) |
0 |
| Other income (expense), net |
426 |
1,970 |
(261) |
| Total other income (expense) |
565 |
2,098 |
(156) |
| Income before provision for income taxes |
43,367 |
32,065 |
31,943 |
| Provision for income taxes |
13,108 |
13,922 |
15,830 |
| Net income |
30,259 |
18,143 |
16,113 |
| Net loss attributable to noncontrolling interest |
876 |
5,381 |
6,906 |
| Net income attributable to Emergent BioSolutions Inc. |
$ 31,135 |
$ 23,524 |
$ 23,019 |
| Earnings per share - basic (in dollars per share) |
$ 0.86 |
$ 0.65 |
$ 0.65 |
| Earnings per share - diluted (in dollars per share) |
$ 0.85 |
$ 0.65 |
$ 0.64 |
| Weighted-average number of shares - basic (in shares) |
36,201,283 |
36,080,495 |
35,658,907 |
| Weighted-average number of shares - diluted (in shares) |
36,747,556 |
36,420,662 |
36,206,052 |